Connect with us
Spanish hospitals are applying AI, deep learning, and digital tools to improve diagnosis, predict disease demand, and enhance prevention. Projects presented at the Gate2Health meeting show...
Saxony’s biotech sector seeks more venture capital, faster approvals, and greater AI use to sustain growth. The state continues investing, expanding hubs like Bioz and Biocity,...
Beeline Medicines launches globally with $300M funding and Bristol Myers Squibb assets to develop precision therapies for autoimmune and inflammatory diseases. Led by Saqib Islam, it...
Novo Nordisk has partnered with OpenAI to use advanced artificial intelligence in drug discovery, data analysis, and operations. The collaboration aims to speed research, improve efficiency...
A 47-year-old woman with three severe autoimmune diseases received CAR-T cell therapy at a German hospital, achieving one-year remission without further treatment. After years of failed...
Gilead is acquiring German biotech firm Tubulis for up to $5 billion, benefiting Evotec, which holds a 3.14 percent stake and expects about $100 million upfront...
Biobanks are vital for advancing rare disease research by enabling access to scarce biological samples. Experts highlighted their role in improving scientific evidence, raising awareness about...
Gilead Sciences focuses on developing treatments for HIV, cancer, and inflammatory diseases, driven by blockbuster drugs like Biktarvy. Growth relies on innovation, patents, and acquisitions. While...
PCSK9 inhibitors have transformed LDL cholesterol management in familial hypercholesterolemia, with new antibodies and CETP inhibitors like obicetrapib expanding options. Statins remain safe and effective, achieving...
Bristol Myers Squibb announced NHS funding for CAR-T therapy Breyanzi, enabling its use from April 1st in Spain for lymphoma treatment. It targets several aggressive subtypes...